Skip to content
2000
Volume 23, Issue 8
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

This article summarizes the importance of different targets such as 5α-reductase, 17β-HSD, CYP17A, androgen receptor and protein kinase A for the treatment of prostate cancer and benign prostatic hyperplasia. It is a well known fact that dihydrotestosterone (DHT) is associated with the development of androgen-dependent afflictions. At the present time, several research groups are attempting to develop new steroidal and non-steroidal molecules with the purpose of inhibiting the synthesis and biological response of DHT. This review also discusses the most recent studies reported in the literature that describe the therapeutic potential of novel compounds, as well as the new drugs, principally inhibitors of 5α-reductase.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867323666160210125642
2016-03-01
2025-07-12
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867323666160210125642
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test